Considering the crucial role of JAK2 during erythropoiesis, it is therefore tempting to hypothesize that the anaemia observed in patients treated with HDAC6i in vivo, and the defect in erythroid differentiation that we observed in vitro are related to an altered HSP90/JAK2 axis. This evidence concerns the gene JAK2 and anemia (phenotype).